Senti Biosciences, Inc. financial data

Symbol
SNTI on Nasdaq
Location
2 Corporate Drive, First Floor, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 337 % -27.7%
Debt-to-equity 187 % +87.4%
Return On Equity -198 % +26.6%
Return On Assets -63.1 % +53.1%
Operating Margin -27.3K % -1781%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.3M shares +473%
Common Stock, Shares, Outstanding 26.3M shares +473%
Entity Public Float 10.8M USD -54%
Common Stock, Value, Issued 3K USD +200%
Weighted Average Number of Shares Outstanding, Basic 26.2M shares +473%
Weighted Average Number of Shares Outstanding, Diluted 26.2M shares +473%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 37.6M USD +5.29%
General and Administrative Expense 28.4M USD +2.93%
Operating Income (Loss) -66.3M USD -4.31%
Nonoperating Income (Expense) 18.7M USD +91.4%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -47.6M USD +61.4%
Earnings Per Share, Basic -3 USD/shares +83.1%
Earnings Per Share, Diluted -3 USD/shares +83.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.2M USD +16.8%
Cash, Cash Equivalents, and Short-term Investments 35.9M USD -63.6%
Accounts Receivable, after Allowance for Credit Loss, Current 567K USD
Other Assets, Current 0 USD -100%
Assets, Current 18.2M USD +4.45%
Property, Plant and Equipment, Net 18.7M USD -15.9%
Operating Lease, Right-of-Use Asset 12.3M USD -15.3%
Other Assets, Noncurrent 34K USD -61.4%
Assets 52.7M USD -8.73%
Accounts Payable, Current 1.77M USD +123%
Employee-related Liabilities, Current 2.12M USD +35%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 12M USD +32.7%
Operating Lease, Liability, Noncurrent 25M USD -17.1%
Other Liabilities, Noncurrent 7.57M USD +198%
Liabilities 44.6M USD +6.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -344M USD -16%
Stockholders' Equity Attributable to Parent 8.12M USD -49.2%
Liabilities and Equity 52.7M USD -8.73%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.1M USD -20.3%
Net Cash Provided by (Used in) Financing Activities -414K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 26.3M shares +473%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.5M USD -23.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.8M USD +12.4%
Deferred Tax Assets, Valuation Allowance 81.7M USD +33.4%
Deferred Tax Assets, Gross 85.4M USD +31.8%
Operating Lease, Liability 30.1M USD -13%
Depreciation 926K USD -5.89%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47.6M USD +32.9%
Lessee, Operating Lease, Liability, to be Paid 39.8M USD -15.7%
Property, Plant and Equipment, Gross 30.9M USD +0.03%
Operating Lease, Liability, Current 5.15M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.77M USD -25.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.71M USD +3.13%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.64M USD -23.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.86M USD -15.8%
Deferred Tax Assets, Operating Loss Carryforwards 51M USD +51.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.38M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5M USD +2.99%
Additional Paid in Capital 352M USD +12.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 4.89M USD -9.72%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%